- Sun Pharma's Q3FY26 consolidated net profit rose 16% to Rs 3,369 crore
- Revenue increased 13.5% to Rs 15,521 crore compared to last year
- EBITDA grew 23.4% to Rs 4,949 crore with a margin of 29.3%
Sun Pharmaceutical Industries Ltd. reported a 16% year-on-year rise in the consolidated net profit to Rs. 3,369 crore in Q3FY26 from Rs. 2,903 crore. Revenue was at Rs. 15,521 crore compared with Rs. 13,676 crore, up 13.5%. Earnings before interest, taxes, depreciation and amortisation was reported to be Rs 4,949 crore versus Rs. 4,009 crore, up 23.4%. Margin is seen at 29.3% versus 31.9%.
Sun Pharmaceutical Industries Q3FY26 results (Cons, YoY)
- Profit Up 16% at Rs 3,369 crore versus Rs 2,903 crore.
- Revenue Up 13.5% at Rs 15,521 crore versus Rs 13,676 crore.
- Ebitda Up 23.4% at Rs 4,949 crore versus Rs 4,009 crore.
- Margin at 29.3% versus 31.9%.
Sun Pharmaceutical Share Price On Sunday
Shares of Sun Pharmaceutical Industries closed 0.36% higher at Rs. 1,595.30 crore on NSE, compared to a 0.39% decrease in the Nifty index on Sunday.
Also Read: Q3 Results LIVE Updates: IDFC First Bank, Sun Pharma, And CDSL Quarterly Earnings Today
Comprehensive Budget 2026 coverage, LIVE TV analysis, Stock Market and Industry reactions, Income Tax changes and Latest News on NDTV Profit.